- Home
- NEXM vs SGMT Comparison
NEXM vs SGMT Comparison
Compare NEXM & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NEXM | SGMT |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 164.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEXM | SGMT |
|---|---|---|
| Price | $3.26 | $5.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 67.9K | ★ 424.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $1.73 |
| 52 Week High | $6.75 | $11.41 |
Technical Indicators
Market Signals| Indicator | NEXM | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 44.60 |
| Support Level | $3.37 | $4.97 |
| Resistance Level | $4.03 | $6.72 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 18.69 | 27.97 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.